Ultime notizie per Astra Exploration (OTC:ATEPF) Azioni

Astra Exploration Inc is a mining exploration company. The company is engaged in acquiring, exploring, and developing epithermal gold-silver properties in Northern Chile and its portfolio contains the Pampa Paciencia Project, the Cerro Bayo Project, and The Other Region.

JP Morgan analyst Patrick Jones downgrades Lundin Mining (TSX:<a class="ticker" href="https://www.benzinga.com/stock/LUN#TSX">LUN</a>) from Overweight to Neutral and raises the price target from C$15.3 to C$15.6.

News

Downgrades

Price Target

Analyst Ratings

TSX:LUN

JP Morgan Downgrades Lundin Mining to Neutral, Raises Price Target to C$15.6

WIIM

Valero Energy shares are trading higher after Piper Sandler maintained an Overweight rating and raised its price target to $160.

Macro Economic Events

Economics

Federal Reserve

Fed's Daly Says I See Two Two Cuts As A Likely Outcome For Fed; There's A Large Amount Of Uncertainty Around Policy Outlook

Fed's Daly Says Labor Market Is Cooling And Growth Is Moderating, But Data Is Not Getting Meaningfully Weaker; Doesn't Expect Very Persistent Inflation Impact From Tariffs; It's Possible Tariffs Don't Create A Large Increase In Prices; It's Time To Think About Adjusting The Interest Rate

IGI Therapeutics SA, a wholly owned subsidiary of New York-based Ichnos Glenmark Innovation Inc., and AbbVie Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), on Thursday, announced an exclusive licensing agreement for IGI&#8217;s lead investigational asset, ISB 2001, developed using IGI&#8217;s proprietary BEAT protein platform, for <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">oncology and autoimmune diseases</a>.
&#8220;Multispecifics including trispecific antibodies represent a new frontier in immuno-oncology with the potential to deliver deeper, more durable responses by engaging multiple targets simultaneously,&#8221; said Roopal Thakkar, AbbVie executive vice-president of research and development, and chief scientific officer.
AbbVie will receive exclusive rights to develop, manufacture and commercialize ISB 2001 across North America, Europe, <a href="https://www.benzinga.com/pressreleases/25/07/g46339734/ichnos-glenmark-innovation-igi-and-abbvie-announce-exclusive-global-licensing-agreement-for-isb-20" target="_blank" rel="noreferrer noopener">Japan and Greater China</a>.
IGI will receive an upfront payment of $700 million and is eligible to receive up to $1.225 billion in development, regulatory, and commercial milestone payments, along with tiered, double-digit royalties on net sales.
ISB&nbsp;2001 is a first-in-class trispecific T-cell engager that targets BCMA and CD38 on myeloma cells and CD3 on T cells. It is currently in Phase&nbsp;1 for relapsed/refractory multiple myeloma.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/large-cap/25/06/46001795/abbvies-migraine-drug-achieves-superiority-in-preventing-headaches-compared-to-generic-treatment-in-head-to-head-trial" rel="noreferrer noopener">AbbVie&#8217;s Migraine Drug Outperforms Generic Treatment In Head-To-Head Trial</a>
Recently presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting as a Rapid Oral Presentation, data from 35 patients demonstrated a sustained overall response rate (ORR) of 79% and a high complete/stringent complete response (CR/sCR) rate of 30% at active doses ≥ 50 µg/kg in a heavily pretreated population of relapsed/refractory myeloma patients, with a favorable safety profile.
U.S. Food &amp; Drug Administration granted ISB&nbsp;2001 Orphan Drug Designation in July 2023 and Fast Track Designation for relapsed/refractory myeloma patients in May 2025.&nbsp;
What&#8217;s Going On With Other Companies: According to a July media report, AstraZeneca Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) was reportedly in talks with Summit Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>) about a partnership <a href="https://www.benzinga.com/news/contracts/25/07/46249640/astrazeneca-in-15b-talks-for-drug-that-could-upend-lung-cancer-treatment" target="_blank" rel="noreferrer noopener">worth up to $15 billion.</a>
The deal would give AstraZeneca the rights to a lung cancer drug called ivonescimab.
In June, BioNTech SE  (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>) and Bristol Myers Squibb &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) entered into a co-development and <a href="https://www.benzinga.com/news/health-care/25/06/45723383/bristol-myers-inks-11-billion-licensing-pact-with-biontech-for-bispecific-cancer-drug" target="_blank" rel="noreferrer noopener">co-commercialization agreement</a>.
The pact focuses on BioNTech's investigational bispecific antibody BNT327 across numerous <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">solid tumor types</a>.
Bristol Myers Squibb will pay BioNTech $1.5 billion upfront and $2 billion in non-contingent anniversary payments through 2028. In addition, BioNTech will be eligible to receive up to $7.6 billion in additional development, regulatory and commercial milestones.
ABBV Price Action: AbbVie stock is up 2.63% at $195.63 at publication on Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/health-care/25/07/46344208/ultragenyx-mereo-shares-dive-as-brittle-bone-disease-drug-misses-early-win" target="_blank" rel="noreferrer noopener">Ultragenyx, Mereo Shares Dive As Brittle Bone Disease Drug Misses Early Win</a></li>
</ul>

Biotech

Large Cap

Health Care

Contracts

Movers

Trading Ideas

General

ABBV

BNTX

SMMT

Why Is AbbVie Stock Trading Higher On Thursday?

DLTR

Dollar Tree shares are trading higher after the company announced a $2.5 billion share repurchase authorization.

Fed's Daly Says The Economy Is In A Good Place, Growth And Jobs Solid, Inflation Easing; Fed Has Ability To Restore Price Stability Gently Given State Of Economy; Monetary Policy Is Still Restrictive

SPDR Dow Jones Industrial Average ETF Trust

Major indexes are higher amid a decline in initial jobless claims.

The evolving landscape of high-performance computing (HPC) is reshaping how investors view traditional <a href="https://www.benzinga.com/topic/bitcoin-mining">bitcoin mining companies</a>, as evidenced by the recent downgrade of Core Scientific, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORZ#NASDAQ">CORZ</a>)
Needham analyst John Todaro downgraded Core Scientific from Buy to Hold. The analyst has not given a price forecast following the downgrade compared to his earlier forecast of $18.
Todaro highlights that the company&#8217;s investment case rests largely on the expanding opportunity in high-performance computing and AI infrastructure.
He notes that among bitcoin miners, Core Scientific stands out as an early mover in what's expected to become a rapidly growing, high-demand space for data center capacity.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-stock-ratings/reiteration/25/07/46306575/why-coreweaves-9-billion-deal-isnt-about-chips" rel="noreferrer noopener">Why CoreWeave&#8217;s $9 Billion Deal Isn&#8217;t About Chips</a>
With the increasing need for computing power to support AI, Bitcoin miners are seen as well-positioned to meet this demand, especially given current constraints on rack space and power.
Todaro notes that CoreWeave, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWV#NASDAQ">CRWV</a>) announced all-stock acquisition of Core Scientific, expected to close in the fourth quarter of 2025, led to a 22% drop in Core Scientific shares—likely due to the stock-only nature of the deal, a lower-than-anticipated valuation, and limited arbitrage potential given CoreWeave&#8217;s borrowing constraints.
As a result, Todaro downgrades Core Scientific, aligning with his CoreWeave downgrade.
He sees the merger as strategically beneficial, adding 150-200MW of IT capacity for CoreWeave, and considers a competing offer from a major hyperscaler unlikely due to existing tenant ties.
While there&#8217;s a chance that Core Scientific shareholders could vote against the deal, insider and board support—representing approximately 14% of shares—makes approval more likely.
Apart from this, Core Scientific has made notable progress in HPC, including a recent multi-year agreement with CoreWeave.
The company now holds contracts for roughly 385 megawatts of HPC co-location capacity, representing over $500 million in potential annual revenue.
Todaro estimates Core Scientific will have 271 megawatts operational by the end of calendar year 2025 and 383 megawatts by the end of 2026, positioning it as one of the first, if not the first, bitcoin miners to bring a 100+ megawatt HPC facility online.
Furthermore, Core Scientific&#8217;s site portfolio is viewed as particularly suited for HPC due to proximity to metro areas and the presence of pre-installed fiber.
These attributes, Todaro adds, reduce the capital costs associated with converting bitcoin mining infrastructure to HPC, especially when compared to competitors operating in West Texas. Given Core Scientific's head start in the HPC space, its cost advantages, and the strong CoreWeave deal, he believes the stock warrants a 15x EV/EBITDA multiple on discounted 2026 projections.
Price Action: CRWV shares are trading lower by 5.19% to $145.17 at last check Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46350022/amazon-prime-day-1-sales-roar-to-7-9-billion-shoppers-slam-website-with-traffic-up-50" target="_blank" rel="noreferrer noopener">Amazon Prime Day 1 Sales Roar To $7.9 Billion, Shoppers Slam Website With Traffic Up 50%+</a></li>
</ul>
Photo: Shutterstock

Equities

Markets

Core Scientific, Inc. - Class A Common Stock

CORZ

CRWV

Core Scientific Downgraded Over Concerns On Acquisition Deal

Scotiabank analyst Konark Gupta maintains Canadian Pacific Kansas (TSX:<a class="ticker" href="https://www.benzinga.com/stock/CP#TSX">CP</a>) with a Sector Outperform and raises the price target from C$115 to C$120.

TSX:CP

Scotiabank Maintains Sector Outperform on Canadian Pacific Kansas, Raises Price Target to C$120

Scotiabank analyst Konark Gupta maintains Cargojet (TSX:<a class="ticker" href="https://www.benzinga.com/stock/CJT#TSX">CJT</a>) with a Sector Outperform and lowers the price target from C$139 to C$138.

TSX:CJT

Scotiabank Maintains Sector Outperform on Cargojet, Lowers Price Target to C$138

<a href="https://www.bloomberg.com/news/articles/2025-07-10/citadel-securities-buys-morgan-stanley-s-options-market-maker?embedded-checkout=true">https://www.bloomberg.com/news/articles/2025-07-10/citadel-securities-buys-morgan-stanley-s-options-market-maker?embedded-checkout=true</a>

'Citadel Securities Buys Morgan Stanley's Options Market Maker'- Bloomberg

Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) has punched through the $113,000 mark, igniting fresh bullish momentum across the crypto market, but some experts caution the rally <a href="https://www.benzinga.com/money/bitcoin-price-prediction">may be short-lived.</a>
What Happened: Crypto trader Jelle compared the move to "a ball breaking above the surface," and suggests it's finally time for Bitcoin to soar.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Like a ball being held underwater. We just broke above the surface &#8211; time to shoot higher.<a href="https://twitter.com/hashtag/Bitcoin?src=hash&amp;ref_src=twsrc%5Etfw">#Bitcoin</a> <a href="https://t.co/8t1PipBaTt">pic.twitter.com/8t1PipBaTt</a>
&mdash; Jelle (@CryptoJelleNL) <a href="https://twitter.com/CryptoJelleNL/status/1943358523339084183?ref_src=twsrc%5Etfw">July 10, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
But not everyone is convinced the path higher will be smooth. 
CoinBureau co-founder Nic Puckrin told Benzinga that this breakout wasn't unexpected, given Bitcoin's recent low volatility and ongoing correlation with tech stocks like Nvidia, which just crossed a $4 trillion market cap.
Puckrin cautions that heavy resistance lies just ahead and warns that profit-taking around $115,000 could cool the momentum. 
He emphasized this move likely isn't the final run-up of the cycle, but rather a "pressure release," possibly followed by a correction and slower summer trading before the next major leg higher.
Also Read: <a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46348748/bitcoins-booming-coinbases-167-rally-says-told-you-so">Bitcoin&#8217;s Booming &#8211; Coinbase&#8217;s 167% Rally Says &#8216;Told You So&#8217;</a>
Why It Matters: According to CryptoQuant analyst Axel Adler Jr., long-term Bitcoin holders (LTHs) have a history of <a href="https://x.com/thecryptobasic/status/1942976175925600550">selling </a>when their unrealized profits reach 300%, often triggering short-term corrections. 
This behaviour was evident during the earlier selloffs near $73,000 and $106,000.
At the current cost basis, Adler estimates Bitcoin would need to hit $137,600 before reaching that 300% unrealized profit threshold again. Until then, some gradual selling may occur, but a major LTH exodus seems unlikely just yet.
Adler also pointed out that BTC typically hits a new all-time high within 50 days of the last one—as long as a 20%+ correction doesn&#8217;t occur—suggesting more upside could follow if momentum holds.
Glassnode reports that a majority of BTC wealth is now held by newer long-term investors. Short-term holder activity remains minimal, reinforcing a more structurally bullish backdrop.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46345201/bitcoins-rally-to-112000-yes-its-different-this-time">Bitcoin&#8217;s Rally To $112,000: Yes, It&#8217;s Different This Time</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

Bitcoin Breaks Above $113,000...But There Is A Catch

Scotiabank analyst Konark Gupta downgrades Mullen Group (TSX:<a class="ticker" href="https://www.benzinga.com/stock/MTL#TSX">MTL</a>) from Sector Outperform to Sector Perform and lowers the price target from C$16.5 to C$16.

TSX:MTL

Scotiabank Downgrades Mullen Group to Sector Perform, Lowers Price Target to C$16

EXPE

NCLH

TRIP

Shares of travel-linked stocks are trading higher following strong earnings from Delta Air Lines.

MRNA

Moderna shares are trading higher after the company received full FDA approval for its COVID-19 vaccine, Spikevax, for children aged 6 months through 11 years at increased risk for COVID-19 disease

<a href="https://azdot.gov/mvd/services/professional-services/autonomous-vehicles-testing-and-operating-state-arizona" title="https://azdot.gov/mvd/services/professional-services/autonomous-vehicles-testing-and-operating-state-arizona">https://azdot.gov/mvd/services/professional-services/autonomous-vehicles-testing-and-operating-state-arizona</a>

TSLA

Reuters Cites Arizona Department Of Transportation Saying Tesla Contacted ADOT MVD On Autonomous Vehicle Ride-Sharing Services On June 26 To Begin Certification Process; Tesla Applied For Both Autonomous Vehicle Testing/Operating With A Driver And Testing/Operating Without A Driver

Vertiv shares are trading lower amid a report suggesting AWS will begin using its own chips for a liquid cooling system.

Barrington Research analyst Michael Petusky maintains Option Care Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPCH#NASDAQ">OPCH</a>) with a Outperform and maintains $38 price target.

OPCH

Barrington Research Maintains Outperform on Option Care Health, Maintains $38 Price Target

President Donald Trump is <a href="https://www.benzinga.com/markets/macro-economic-events/25/07/46269036/scott-bessent-says-tariff-rates-set-to-boomerang-back-in-august-for-countries-faili">sticking to his Aug. 1 deadline</a> to reimpose steep tariffs, but the stock market doesn&#8217;t seem too worried. On Reddit&#8217;s <a href="https://www.reddit.com/r/stocks/comments/1luos7o/so_why_is_the_stock_market_completely_ignoring/">r/stocks</a>, one confused investor posted, &#8220;Trump just announced plans to do <a href="https://www.benzinga.com/markets/25/05/45486508/scott-bessent-signals-liberation-day-2-0-coming-if-countries-dont-sign-trade-deals-president-trump-has-put-them-on-notice">Liberation Day 2.0</a> all over again, but this time the stock market stays&#8230; up??? Does Wall Street simply not care about the economy anymore?&#8221;
<h2 class="wp-block-heading">Markets Shrug Off Tariff Threats</h2>
Wall Street dipped slightly on Tuesday, with the <a href="https://finance.yahoo.com/news/live/stock-market-today-dow-sp-500-slip-as-trump-stays-firm-on-august-tariff-deadline-announces-copper-duties-200133528.html">Dow falling</a> about 0.4% and the S&amp;P 500 slipping just 0.07%. The Nasdaq barely edged higher. These modest moves followed Trump&#8217;s declaration on <a href="https://truthsocial.com/@realDonaldTrump/posts/114818149310161097">Truth Social</a> that there would be &#8220;no extensions granted&#8221; beyond the Aug. 1 deadline, adding that countries should expect to start paying new tariffs on that day. He also announced a <a href="https://www.benzinga.com/markets/equities/25/07/46305321/copper-price-surges-trump-tariffs-stocks-july-2025">50% tariff on copper imports</a> and threatened tariffs as high as 200% on pharmaceuticals.
Don't Miss:
<ul class="wp-block-list">
<li>Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die."<a href="https://www.benzinga.com/money/warren-buffet-make-money-when-you-sleep"> Here&#8217;s how you can earn passive income with just $10.</a></li>
<li>$100k+ in investable assets? <a href="https://www.benzinga.com/money/wiseradvisor-retirement-planning">Match with a fiduciary advisor for free to learn how you can maximize your retirement and save on taxes</a> – no cost, no obligation.</li>
</ul>
Despite the tough talk, many investors aren't reacting the <a href="https://www.benzinga.com/25/04/44710082/trumps-liberation-day-tariffs-wipe-out-174-billion-from-the-net-worth-of-worlds-top-10-billionaires-including-warren-buffett">way they did</a> when Trump tariffs were announced on April 2, a date he referred to as &#8220;Liberation Day&#8221;.
One Reddit user boiled it down like this: &#8220;Because no one is believing the boy who cried tariff.&#8221;
That skepticism is widespread. In the Reddit thread, a term kept popping up: TACO, short for &#8220;Trump Always Chickens Out.&#8221; It&#8217;s <a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/25/06/46180782/trumps-tariff-clock-ticks-but-taco-traders-arent-losing-their-cool">Wall Street slang</a> that reflects a belief that Trump often makes bold announcements but backs down before serious consequences hit. &#8220;It took him like an hour yesterday to start saying that the new date isn&#8217;t 100%,&#8221; another commenter noted.
Others pointed out that the market has already priced in much of the tariff risk. &#8220;When he threatened with a +50% range, the market panicked. Now the tariffs are landing in the range that the market initially anticipated,&#8221; one top commenter explained, referencing the expected 10% to 25% tariff range.
Trending: The secret weapon in billionaire investor portfolios that you almost certainly don't own yet. <a href="https://www.benzinga.com/money/masterworks">See which asset class has outpaced the S&amp;P 500 (1995-2024) – and with near-zero correlation.</a>
Even Trump's newly announced copper tariff pushed futures up more than 10%, while pharmaceutical stocks like Pfizer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) and Amgen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) pulled back after an early rally. Amazon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) also <a href="https://www.benzinga.com/trading-ideas/movers/25/07/46302633/amazon-stock-slips-as-early-prime-day-sales-data-disappoints">slipped</a> about 1% as its extended Prime Day began, with some investors watching for signs that tariffs are inflating consumer prices.
Still, some think the market is underestimating the damage. &#8220;We won't really know the impact until the fall,&#8221; one Reddit investor cautioned, suggesting that companies might temporarily absorb costs before passing them on.
In short, traders may have grown numb to Trump's tariff threats. &#8220;The market believes Trump isn&#8217;t serious and will back down before any real consequences emerge,&#8221; one commenter said. Another added: &#8220;Eventually he won&#8217;t chicken out,&#8221; hinting that investor complacency could backfire if Trump follows through this time.
For now, Wall Street appears more focused on Federal Reserve policy and the upcoming Q2 earnings season.&nbsp;
As one Redditor put it, &#8220;The stock market isn&#8217;t the economy.&#8221;
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/money/gbr-savings-by-age">If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</a></li>
<li>Over the last five years, the price of gold has increased by approximately 83% — Investors like Bill O&#8217;Reilly and Rudy Giuliani are using this platform to <a href="https://www.benzinga.com/money/american-hartford-gold">create customized gold IRAs to help shield their savings from inflation and economic turbulence. </a></li>
</ul>
Image: Shutterstock

AMGN

AMZN

An Investor Wonders Why Trump's Tariffs Aren't Shaking The Markets. 'Does Wall Street Simply Not Care About The Economy Anymore?'

Press Releases

Astra Provides Update on Drill Program at La Manchuria Project, Argentina

Astra Drills 1.4m Grading 35.3g/t Gold and 8,356 g/t Silver At La Manchuria Project, Santa Cruz, Argentina

Astra Exploration to Host Investor Webinar with Presentation and Audience Q&A

Astra Intersects 199.3g/t Gold and 228g/t Silver Over 0.6 Meters and Multiple High-Grade Veins at La Manchuria, Argentina

ATEPF

TSXV:ASTR

ASTRA EXPLORATION INC by Astra Exploration Inc.

Astra Exploration

Comments

Astra Exploration

Notizie

Ultime notizie per Astra Exploration (OTC:ATEPF) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO